已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis

医学 内科学 肿瘤科 奥西默替尼 吉非替尼 肺癌 表皮生长因子受体 养生 培美曲塞 无进展生存期 埃罗替尼 临床终点 不利影响 随机对照试验 科克伦图书馆 化疗 癌症 顺铂
作者
Fei Yang,Wengang Zhang,Xiaoling Shang,Ni Liu,Xinchun Ma,Jing Qin,Yuqing Zhang,Yanguo Liu,Xiuwen Wang
出处
期刊:Critical Reviews in Oncology Hematology [Elsevier BV]
卷期号:177: 103760-103760 被引量:14
标识
DOI:10.1016/j.critrevonc.2022.103760
摘要

A growing number of regimens have been approved as first-line treatments for patients with advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer. However, the optimal regimen has not been determined, especially for patients with different clinicopathological characteristics. Therefore, we performed this meta-analysis to compare the efficacy and safety of first-line treatments for patients with EGFR-mutated NSCLC based on clinicopathological characteristics, thereby providing evidence for individual patient clinical decision-making.The PubMed, Embase, Cochrane Library databases, and abstracts of ASCO, ESMO, and WCLC were searched from inception to 3 June 2021 to identify eligible randomized controlled trials (RCTs). The outcomes of progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and grade 3 or higher adverse events (≥3AEs) were compared and ranked based on various clinicopathological characteristics among 14 regimens by network meta-analysis (NMA) and the surface under the cumulative ranking curve (SUCRA), respectively.25 RCTs were included, with a total of 6965 patients and 14 treatment regimens. The primary endpoint of all RCTs was PFS, and OS, ORR, and ≥3AEs were secondary endpoints. Regarding overall patients, the most distinct PFS benefit was observed in osimertinib (OSI), with the fewest ≥3AEs, whereas gefitinib plus pemetrexed-based chemotherapy (GEF+PB) provided the greatest benefit for OS. When considering EGFR mutation type, aumolertinib (AUM) and GEF+PB could be the optimal regimens in terms of PFS for patients with EGFR 19DEL and EGFR 21L858R, respectively. Notably, the efficacy of the 14 regimens for PFS varied across clinicopathological characteristics, with GEP+PB ranking first in Eastern Cooperative Oncology Group performance status (ECOG PS)= 1, Asian, age<65 and smoking subgroups, with AUM ranking first in ECOG PS= 0 and female subgroups, with ICO+PB ranking first in age ≥65 and no smoking subgroups, and with AFA+CET ranking first in the male subgroup. In terms of brain metastases, third-generation EGFR-TKI showed obvious superiority, with AUM and OSI optimally prolonging PFS in patients with and without brain metastases, respectively. In addition, GEF+PB is a superior alternative, ranking second in terms of PFS regardless of the presence of brain metastases.OSI and GEF+PB were the most two effective first-line regimens for overall patients, ranking first in PFS and OS, respectively. GEF+PB ranked first in terms of PFS in subgroups of EGFR 21L858R, ECOG PS= 1, Asian, age <65, and smoking. Meanwhile, AUM in subgroups of EGFR 19DEL, ECOG PS= 0, female, brain metastasis, OSI in the subgroup of without brain metastasis, ICO+PB in no smoking subgroup, and AFA+CET in male subgroup were the best options as for their evident superiority in PFS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
天天快乐的应助被刘刘采纳,获得30
2秒前
2秒前
地西他滨发布了新的文献求助10
3秒前
疏水无纺布完成签到,获得积分10
3秒前
jing32yi完成签到,获得积分10
3秒前
青年才俊发布了新的文献求助10
3秒前
长情靖雁完成签到,获得积分10
4秒前
4秒前
LOVE17发布了新的文献求助10
6秒前
7秒前
布里田完成签到 ,获得积分10
7秒前
Hello的应助被Victoria采纳,获得10
8秒前
8秒前
王王碎冰冰完成签到,获得积分10
9秒前
小二郎的应助被Tsuki采纳,获得10
9秒前
9秒前
失眠念柏完成签到 ,获得积分10
10秒前
歪特发布了新的文献求助10
10秒前
Brave发布了新的文献求助80
11秒前
12秒前
13秒前
甜蜜元绿完成签到,获得积分10
14秒前
ke发布了新的文献求助10
14秒前
袁123发布了新的文献求助10
15秒前
LSH发布了新的文献求助10
15秒前
16秒前
CipherSage的应助被yy睡不醒采纳,获得30
17秒前
17秒前
尊嘟假嘟的应助被TaraMorgan125采纳,获得40
18秒前
stoneco完成签到,获得积分20
18秒前
19秒前
小手冰凉完成签到 ,获得积分10
19秒前
传奇3的应助被horse82采纳,获得10
19秒前
仁爱的梦曼完成签到,获得积分10
19秒前
Shirong_Peng发布了新的文献求助10
19秒前
20秒前
沧海一笑完成签到 ,获得积分10
20秒前
sun发布了新的文献求助10
22秒前
YAN0221发布了新的文献求助10
22秒前
打球的篮完成签到,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194470
求助须知:如何正确求助?哪些是违规求助? 9580227
关于积分的说明 21870293
捐赠科研通 7794034
什么是DOI,文献DOI怎么找? 3437667
关于科研通互助平台的介绍 2560986
邀请新用户注册赠送积分活动 2484393